HRP20210933T1 - Dijagnostički reagensi za unaprijeđenu in vivo ili in vitro stanično-posredovanu imunološku dijagnozu tuberkuloze - Google Patents
Dijagnostički reagensi za unaprijeđenu in vivo ili in vitro stanično-posredovanu imunološku dijagnozu tuberkuloze Download PDFInfo
- Publication number
- HRP20210933T1 HRP20210933T1 HRP20210933TT HRP20210933T HRP20210933T1 HR P20210933 T1 HRP20210933 T1 HR P20210933T1 HR P20210933T T HRP20210933T T HR P20210933TT HR P20210933 T HRP20210933 T HR P20210933T HR P20210933 T1 HRP20210933 T1 HR P20210933T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- composition according
- diagnostic composition
- fragments
- Prior art date
Links
- 201000008827 tuberculosis Diseases 0.000 title claims 6
- 238000003745 diagnosis Methods 0.000 title claims 3
- 238000000338 in vitro Methods 0.000 title claims 3
- 238000001727 in vivo Methods 0.000 title claims 2
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 230000001900 immune effect Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 18
- 230000002163 immunogen Effects 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 150000001413 amino acids Chemical class 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 241001467553 Mycobacterium africanum Species 0.000 claims 2
- 241000186366 Mycobacterium bovis Species 0.000 claims 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Claims (14)
1. Dijagnostička kompozicija koja sadrži mješavinu suštinski čistih polipeptida koji se sastoje od
a) aminokiselinske sekvence Rv3874 (SEQ ID NO 1), Rv3615 (SEQ ID NO 2) i Rv2348 (SEQ ID NO 4);
ili
b) fragmenata od 6-50 aminokiselina dužine iz aminokiselinske sekvence Rv3874 (SEQ ID NO1), fragmenata od 6-50 aminokiselina dužine iz aminokiselinske sekvence Rv3615 (SEQ ID NO 2) i fragmenata od 6-50 aminokiselina dužine iz aminokiselinske sekvence Rv2348 (SEQ ID NO 4), i pri čemu svaki fragment sadrži imunogene epitope iz navedenih aminokiselinskih sekvenci;
ili
c)
(i) aminokiselinskih sekvenci koje imaju najmanje 80% identičnosti sa aminokiselinskim sekvencama Rv3874 (SEQ ID NO1) i koje su u isto vrijeme imunogene, aminokiselinskih sekvenci koje imaju najmanje 80 % identičnosti sa aminokiselinskim sekvencama Rv3615 (SEQ ID NO 2) i koje su u isto vrijeme imunogene i aminokiselinskih sekvenci koje imaju najmanje 80% identičnosti sa aminokiselinskim sekvencama Rv2348 (SEQ ID NO 4) i koje su u isto vrijeme imunogene ili
(ii) aminokiselinskih sekvenci koje imaju 80% identičnosti sa fragmentima od 6-50 aminokiselina dužine iz aminokiselinske sekvence Rv3874 (SEQ ID NO1) i da su u isto vrijeme imunogene, fragmenata od 6-50 aminokiselina dužine iz aminokiselinske sekvence Rv3615 (SEQ ID NO 2) i da su u isto vrijeme imunogeni i fragmenata od 6-50 aminokiselina dužine iz aminokiselinske sekvence Rv2348 (SEQ ID NO 4) i da su u isto vrijeme imunogeni.
2. Dijagnostička kompozicija prema patentnom zahtjevu 1, koja dodatno sadrži (i) Rv3865 (SEQ ID NO 3) ili njegove fragmente koji sadrže imunogene epitope; ili (ii) Rv3877 (SEQ ID NO 7) ili njegove fragmente koji sadrže imunogene epitope.
3. Dijagnostička kompozicija prema patentnim zahtjevima 1 ili 2, naznačena time da su fragmenti koji sadrže imunogene epitope sekvence SEQ ID NO 1 izabrani između sekvenci SEQ ID NO 9-14; i/ili fragmenti koji sadrže imunogene epitope iz sekvence SEQ ID NO 2 izabrani su između SEQ ID NO 15-18 ili SEQ ID NO 59-63; i/ili fragmenti koji sadrže imunogene epitope iz sekvence SEQ ID NO 3 izabrani su između SEQ ID NO 19-21; i/ili fragmenti koji sadrže imunogene epitope sekvence SEQ ID NO 4 izabrani su između SEQ ID NO 22-25; i/ili fragmenti koji sadrže imunogene epitope sekvence SEQ ID NO 7 izabrani su između sekvenci SEQ ID NO 46-50.
4. Dijagnostička kompozicija prema patentnim zahtjevima 1-3, koja dodatno sadrži Rv3875 (SEQ ID NO 51) ili jedan ili više njegovih fragmenata.
5. Dijagnostička kompozicija prema patentnom zahtjevu 4, naznačena time da su fragmenti ili fragmenti koji sadrže imunogene epitope sekvence SEQ ID NO 51 izabrani između sekvenci SEQ ID NO 52-58.
6. Dijagnostička kompozicija prema bilo kojem od patentnih zahtjeva 1-5, naznačena time da su fragmenti koji sadrže imunogene epitope naznačenih polipeptida prisutni u vidu preklapajućih polipeptida od najmanje 10 aminokiselina dužine.
7. Dijagnostička kompozicija prema patentnom zahtjevu 2(i), u kojoj mješavina sadrži sekvence SEQ ID NO 9 - 25.
8. Dijagnostička kompozicija prema bilo kojem od prethodnih zahtjeva, naznačena time da su neki ili svi polipeptidi međusobno stopljeni, izborno, preko veznika ili razdjelnika.
9. CMI dijagnostički alat ili komplet, koji sadrži dijagnostičku kompoziciju prema patentnim zahtjevima 1-8.
10. CMI dijagnostički alat ili komplet prema patentnom zahtjevu 9, za in vitro ili in vivo dijagnosticiranje tuberkuloze.
11. Postupak in vitro dijagnosticiranja tuberkuloze izazvane virulentnim mikobakterijama, na primjer od Mycobacterium tuberculosis, Mycobacterium africanum ili Mycobacterium bovis, kod životinja, uključujući i ljude, primjenom dijagnostičke kompozicije prema patentnim zahtjevima 1-8.
12. Dijagnostička kompozicija prema bilo kojem od patentnih zahtjeva 1-8, za primjenu u postupku dijagnosticiranja, naznačeno time da postupak obuhvaća intradermalnu injekciju dijagnostičke kompozicije, gdje pozitivni rezultat kožnog testa na mjestu injekcije kod životinje ukazuje da životinja ima tuberkulozu, a negativan kožni test na mjestu injekcije ukazuje da životinja nema tuberkulozu.
13. Dijagnostička kompozicija prema patentnom zahtjevu 11, koja sadrži uzorak, na primjer, uzorak krvi, sa dijagnostičkom kompozicijom prema pronalasku, u cilju detektiranja pozitivne reakcije, na primjer, proliferacije stanica ili oslobađanja citokina, kao što su IFN-γ ili IP-10.
14. Dijagnostička kompozicija prema bilo kojem od patentnih zahtjeva 1 do 8, za primjenu u postupcima dijagnosticiranja tuberkuloze izazvane sojevima virulentnih mikobakterija, na primjer od Mycobacterium tuberculosis, Mycobacterium africanum ili Mycobacterium bovis, kod životinja, uključujući ljude, izborno, naznačeno time da se uzorak, na primjer, uzorak krvi, dovodi u kontakt sa dijagnostičkom kompozicijom prema pronalasku, kako bi se detektirala pozitivna reakcija, na primjer, proliferacija stanica ili oslobađanje citokina, kao što su IFN-γ ili IP-10.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201300698 | 2013-12-16 | ||
| PCT/DK2014/000062 WO2015090322A1 (en) | 2013-12-16 | 2014-12-15 | Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis |
| EP14845019.0A EP3084442B1 (en) | 2013-12-16 | 2014-12-15 | Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210933T1 true HRP20210933T1 (hr) | 2021-09-03 |
Family
ID=52686037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210933TT HRP20210933T1 (hr) | 2013-12-16 | 2021-06-10 | Dijagnostički reagensi za unaprijeđenu in vivo ili in vitro stanično-posredovanu imunološku dijagnozu tuberkuloze |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10641770B2 (hr) |
| EP (1) | EP3084442B1 (hr) |
| JP (1) | JP6698530B2 (hr) |
| KR (1) | KR102305770B1 (hr) |
| CN (1) | CN105829891B (hr) |
| AU (1) | AU2014365971B2 (hr) |
| CA (1) | CA2933817C (hr) |
| DK (1) | DK3084442T3 (hr) |
| EA (1) | EA201691091A1 (hr) |
| ES (1) | ES2875021T3 (hr) |
| HR (1) | HRP20210933T1 (hr) |
| HU (1) | HUE054800T2 (hr) |
| LT (1) | LT3084442T (hr) |
| PL (1) | PL3084442T3 (hr) |
| PT (1) | PT3084442T (hr) |
| RS (1) | RS61977B1 (hr) |
| SI (1) | SI3084442T1 (hr) |
| WO (1) | WO2015090322A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107045065A (zh) * | 2017-02-07 | 2017-08-15 | 广州市宝创生物技术有限公司 | 结核快速诊断试剂盒及其制备方法 |
| KR101923198B1 (ko) * | 2017-09-25 | 2018-11-28 | 주식회사 엠디엡투스 | Tb7.7에 특이적으로 결합하는 dna 압타머 및 이의 용도 |
| KR102157770B1 (ko) * | 2019-01-11 | 2020-09-18 | 주식회사 파이지노믹스 | 가축의 결핵 진단을 위한 항원 펩타이드 조성물 및 이의 용도 |
| GB201906193D0 (en) * | 2019-04-10 | 2019-06-19 | Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency | Diagnostic reagents |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5075969B2 (ja) * | 1999-07-13 | 2012-11-21 | スタテンズ セーラム インスティテュート | マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法 |
| EP1200466A2 (en) * | 1999-07-13 | 2002-05-02 | Statens Serum Institut | Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosisesat-6 gene family |
| WO2004099771A1 (en) * | 2003-05-08 | 2004-11-18 | Statens Serum Institut | A new specific epitope based immunological diagnosis of tuberculosis |
| GB0906215D0 (en) | 2009-04-09 | 2009-05-20 | Lalvani Ajit | Diagnostic test |
| MX370744B (es) * | 2009-04-24 | 2019-12-20 | Una vacuna antituberculosis tb para evitar la reactivación. | |
| ITRM20100411A1 (it) * | 2010-07-23 | 2012-01-24 | Massimo Amicosante | Uso di sequenze amminoacidiche da mycobacterium tuberculosis o dei loro corrispondenti acidi nucleici per la diagnosi e la prevenzione di infezione tubercolare, relativo kit diagnostico e vaccino. |
| US20130345079A1 (en) * | 2010-10-27 | 2013-12-26 | Infectious Disease Research Institute | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity |
| WO2012167307A1 (en) * | 2011-06-06 | 2012-12-13 | The University Of Melbourne | Diagnosis of mycobacterial infection |
| CN102608333B (zh) * | 2012-03-30 | 2013-06-05 | 中国科学院微生物研究所 | 一种结核诊断组合物及其应用 |
-
2014
- 2014-12-15 RS RS20210752A patent/RS61977B1/sr unknown
- 2014-12-15 EP EP14845019.0A patent/EP3084442B1/en active Active
- 2014-12-15 HU HUE14845019A patent/HUE054800T2/hu unknown
- 2014-12-15 WO PCT/DK2014/000062 patent/WO2015090322A1/en active Application Filing
- 2014-12-15 CN CN201480068708.9A patent/CN105829891B/zh active Active
- 2014-12-15 ES ES14845019T patent/ES2875021T3/es active Active
- 2014-12-15 DK DK14845019.0T patent/DK3084442T3/da active
- 2014-12-15 PT PT148450190T patent/PT3084442T/pt unknown
- 2014-12-15 PL PL14845019T patent/PL3084442T3/pl unknown
- 2014-12-15 LT LTEP14845019.0T patent/LT3084442T/lt unknown
- 2014-12-15 AU AU2014365971A patent/AU2014365971B2/en active Active
- 2014-12-15 SI SI201431833T patent/SI3084442T1/sl unknown
- 2014-12-15 KR KR1020167018564A patent/KR102305770B1/ko active IP Right Grant
- 2014-12-15 JP JP2016539075A patent/JP6698530B2/ja active Active
- 2014-12-15 US US15/104,957 patent/US10641770B2/en active Active
- 2014-12-15 EA EA201691091A patent/EA201691091A1/ru unknown
- 2014-12-15 CA CA2933817A patent/CA2933817C/en active Active
-
2021
- 2021-06-10 HR HRP20210933TT patent/HRP20210933T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS61977B1 (sr) | 2021-07-30 |
| CN105829891B (zh) | 2018-04-06 |
| PT3084442T (pt) | 2021-06-22 |
| US10641770B2 (en) | 2020-05-05 |
| EP3084442A1 (en) | 2016-10-26 |
| SI3084442T1 (sl) | 2021-08-31 |
| WO2015090322A8 (en) | 2016-07-21 |
| CA2933817A1 (en) | 2015-06-25 |
| JP2017503161A (ja) | 2017-01-26 |
| BR112016013915A2 (pt) | 2018-01-09 |
| JP6698530B2 (ja) | 2020-05-27 |
| DK3084442T3 (da) | 2021-06-21 |
| US20170016897A1 (en) | 2017-01-19 |
| KR102305770B1 (ko) | 2021-09-29 |
| AU2014365971A8 (en) | 2016-08-25 |
| LT3084442T (lt) | 2021-07-12 |
| AU2014365971B2 (en) | 2021-02-04 |
| PL3084442T3 (pl) | 2021-10-25 |
| AU2014365971A1 (en) | 2016-06-30 |
| HUE054800T2 (hu) | 2021-09-28 |
| WO2015090322A1 (en) | 2015-06-25 |
| CN105829891A (zh) | 2016-08-03 |
| CA2933817C (en) | 2023-04-04 |
| ES2875021T3 (es) | 2021-11-08 |
| KR20160097325A (ko) | 2016-08-17 |
| EA201691091A1 (ru) | 2016-12-30 |
| EP3084442B1 (en) | 2021-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210933T1 (hr) | Dijagnostički reagensi za unaprijeđenu in vivo ili in vitro stanično-posredovanu imunološku dijagnozu tuberkuloze | |
| Coppola et al. | Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination | |
| Vordermeier et al. | Bovine tuberculosis in cattle: vaccines, DIVA tests, and host biomarker discovery | |
| Pollock et al. | Pathogenesis of bovine tuberculosis: the role of experimental models of infection | |
| Uplekar et al. | Comparative genomics of Esx genes from clinical isolates of Mycobacterium tuberculosis provides evidence for gene conversion and epitope variation | |
| Waters et al. | Relevance of bovine tuberculosis research to the understanding of human disease: historical perspectives, approaches, and immunologic mechanisms | |
| EA201590184A1 (ru) | Вакцина на основе микобактериальных антигенов | |
| Bottai et al. | Mycobacterial pathogenomics and evolution | |
| BR112017010268A2 (pt) | agente de ligação; composição de diagnóstico; kit de diagnóstico; métodos de diagnóstico de uma infecção bacteriana ou de diferenciação entre uma infecção bacteriana e uma infecção de viral; para descartar uma infecção bacteriana em um indivíduo; para descartar uma infecção viral em um indivíduo; para considerar uma infecção bacteriana em um indivíduo; para considerar uma infecção viral em um indivíduo; para distinguir entre uma infecção bacteriana ou mista e uma infecção viral em um indivíduo; para fornecer uma recomendação de tratamento para um indivíduo; para fornecer uma recomendação de teste de diagnóstico para um indivíduo; para descartar uma doença infecciosa; para identificação do tipo de infecção; e dispositivo para o diagnóstico de infecções bacterianas | |
| BR112015009070A2 (pt) | proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas | |
| Wagemakers et al. | Rapid outer-surface protein C DNA tattoo vaccination protects against Borrelia afzelii infection | |
| JP2017503161A5 (hr) | ||
| AR101715A1 (es) | Composiciones útiles para diagnosticar infección latente por mycobacterium tuberculosis | |
| NZ603053A (en) | Diagnostic reagents | |
| Costa et al. | Comparison of interferon-γ release assay and tuberculin test for screening in healthcare workers | |
| Birhanu et al. | Review on diagnostic techniques of bovine tuberculosis in Ethiopia | |
| Mon et al. | Evaluation of cocktails with recombinant proteins of Mycobacterium bovis for a specific diagnosis of bovine tuberculosis | |
| Katalinic-Jankovic et al. | Microbiology of Mycobacterium tuberculosis and a new diagnostic test for TB | |
| Mertaniasih et al. | Sequence analysis of the gene region encoding ESAT-6, Ag85B, and Ag85 C proteins from clinical isolates of Mycobacterium tuberculosis | |
| Vordermeier et al. | Development of cattle TB vaccines in the UK | |
| Mirlekar et al. | Mycobacterium tuberculosis: approach to development of improved strategies for disease control through vaccination and immunodiagnosis | |
| Sato et al. | The clinical application of quantiferon TB-2G: its usefulness and limitations | |
| Savova-Lalkovska et al. | Evaluation of classical and rapid methods for isolation and identification of Mycobacterium bovis in cattle in Bulgaria. | |
| Doherty et al. | Tuberculosis vaccines: developmental work and the future | |
| SHURALEV et al. | Cattle Tuberculosis and eir Vectors: Tools for Early Detection of Biological Risks of the Disease¹ |